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which could be attributed to various pharmacological interventions. The critical 
appraisal concluded that the studies were of moderate quality. ConClusions: 
The majority of included RCTs used HF-specific questionnaires, to measure QoL. 
From 2009 onwards, the use of KCCQ increased compared to MLHFQ and KCCQ was 
administered to a comparatively larger study population. Thus, QoL data retrieved 
from studies using KCCQ are considered to be more representative of the real world. 
The inconsistency in reporting of QoL results in RCTs limited comparison of the 
treatment impact on QoL
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objeCtives: In Germany, apheresis is indicated for patients on maximally tolerated 
lipid lowering therapy (max LLT) with uncontrolled low density lipoprotein (LDL) 
levels over 12 months. The current application process restricts patients’ access 
to apheresis although no other treatments are available. Despite its burdensome 
nature and invasiveness, this procedure offers an additional LDL lowering when max 
LLTs are insufficient. This psychodrama market-research aimed to understand the 
patients’ perception of apheresis and how apheresis affects daily living. The core 
concept is to ‘ask without asking’. Methods: Eligible patients had severe hyper-
cholesterolemia, ≥ 1 cardiovascular event, apheresis, and were ≤ 72 years of age. 
The conducted workshops focused on the following topics: 1) disease perception 2) 
perception of apheresis 3) anticipated impact of new therapies on patients’ quality 
of life (QoL). Psychodrama techniques were used to investigate and gain insight into 
the perceptional and emotional world of the patients. A QoL questionnaire (SF-36) 
was applied before (QoL with apheresis) and after the workshop (imagination of 
QoL with a new therapy option). Results: Four workshops took place in October 
2014 in Munich (n= 2), Berlin and Frankfurt. The average age was 63 years (N= 26) 
and patients had broad experience with apheresis. The assessment on the disease 
perception led to feedbacks such as, “It doesn’t hurt and that is bad!”, “My whole 
life changed” or “The fear is in my head!”. Perception of apheresis was ambiguous 
revealing cons (“invasive”, “time-consuming”) and pros (“life-saver”, “effective”). The 
SF-36 evaluation demonstrated an increase in the overall QoL state for the majority 
of patients (n= 20). CONCLUSIONS: Apheresis is seen as burdensome but neces-
sary. Without alternatives, apheresis is considered important by patients, however, 
patients are eager to try new therapies offering more efficacious disease control 
and thereby avoidance of apheresis.
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objeCtives: To quantify preference weights (including willingness to pay = WTP) 
for attributes of a bedside pharmacogenetic test for the CYP2C19*2 allele to permit 
personalization of antiplatelet therapy in patients with acute coronary syndromes 
(ACS). Methods: This internet-based survey tool comprised of: patient demo-
graphics, a decision board and choice sets. Context was provided by way of a deci-
sion board that offered three treatment alternatives for hypothetical ACS patients, 
one of which offered pharmacogenetic testing. Respondents choosing the pharma-
cogenetic option were provided with 8 choice sets; each with two alternatives. Each 
alternative consisted of three attributes, each with three levels. Attributes (levels) 
included: how sample was taken (cheek swab, finger prick or draw blood); turna-
round time for results (1 hour, 3 days, 1 week), and cost expressed as an additional 
annual insurance premium in Canadian dollars (C$)(C$0, C$2, C$10). A full factorial 
design was implemented. A conditional logit regression model was used to analyze 
the responses. The survey was disseminated to randomly selected respondents in 
Ontario (Canada), stratified by age, gender and education. Results: Results are 
generalizable to the Ontario population. Among 328 respondents who completed 
an informed consent for the survey, 219 chose the pharmacogenetic test option 
providing 3472 observations. Exponential coefficients (standard errors) and p val-
ues are as follows: Turnaround; 1 week = 0.089 (0.13) p< 0.0001, 3 days = .243 (0.113) 
p< 0.0001, Sample extraction; finger prick = 1.043 (0.104) p= 0.683, cheekswab = 
1.140 (0.100) = 0.19, cost = 0.63127 (0.032) p< 0.001. WTP in additional annual insur-
ance premiums is C$5.18 for one hour over a 7 day turnaround time and C$3.06 
over a 3 day turnaround. ConClusions: Respondents were 11 times as likely to 
choose a 1 hour turnaround time, and tended to prefer the cheekswab method. 
An incremental WTP was observed for more expedient sample turnaround 
time.
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objeCtives: Heart failure (HF) is an important public health problem that 
depletes a large quantity of health resources. Around 2% of the adult popula-
tion in developed countries suffers from HF. The high prevalence of HF in Spain, 
around 5%, is mostly determined by its population’s progressive ageing. This study 
describes the impact of HF on hospital admissions, length of stay, hospitalization 
confirmed that patients who had a greater improvement in 6MWD (> 40m) at week 
12 of the study had higher mean scores than those with lower improvement (< 40m). 
Furthermore, patients with better functional ability according to WHO classifica-
tion had higher EQ-5D utility scores than those with lower ability. ConClusions: 
Results demonstrate the positive impact of riociguat on patient-reported health 
status among CTEPH patients.
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objeCtives: Hypertension has few subjective symptoms and its treatment must 
be continued long term, as patients may stop visiting the hospital regularly and 
give up on lifestyle improvements. Therefore, the effective and brief coaching-style 
intervention program is essential in community pharmacies. The objective of this 
study was to investigate the effect of intervention by community pharmacists on the 
awareness of continuing treatment among patients with hypertension. Methods: 
This study was designed as a cluster-randomized controlled trial with a 3-month 
intervention period. The subjects comprised adult patients with essential hyper-
tension who had been taking antihypertensive medication for at least 3 months. 
Patients in the intervention group underwent a motivational interview with a phar-
macist lasting around 3 minutes each time they received a prescription, while those 
in the observation group were provided with usual care. Both groups’ patients were 
provided with a home blood pressure monitoring device and pedometer. The study 
outcome was awareness of the continuation of regular hospital visits, healthy diet, 
and appropriate exercise, rated on a 10-point scale from “Extremely important” to 
“Not at all important.” Results: Responses were obtained from 114 patients at 55 
pharmacies (intervention group: 28, observation group: 27). that had enrolled in the 
study A comparison of awareness before and after intervention showed that only 
awareness of regular hospital visits had improved in the observation group (p = 
0.03), whereas in the intervention group, awareness of both regular hospital visits 
(p = 0.04) and appropriate exercise (p = 0.02) showed improvement. ConClusions: 
The findings of this study revealed that intervention by community pharmacists 
may contribute to raising awareness of the need to continue exercise. This result 
implies that pharmacist can improve patients’ ability to chronic disease manage-
ment.
PCV143
The QuAliTy of life in PATienTs 12 monThs AfTer An ACuTe CoronAry 
syndrom: resulTs from The PGrx-3 reAl World dATAseT
Nordon C1, Abenhaim L2, Worsfold A2, Amzal B2, Rossignol M3, Grimaldi-Bensouda L1
1LASER Research, Paris, France, 2LASER Analytica, London, UK, 3McGill University, Montreal, QC, 
Canada
objeCtives: To measure the quality of life (QoL) of patients 12 months after an 
acute coronary syndrome (ACS) Methods: PGRx-3 are multiusers, multi-countries, 
prospective Real World Datasets assembled to describe disease risk factors, burden 
of disease, disease management, treatment patterns and patient quality of life; they 
are also used for the study of the effectiveness and relative risk of medicines. More 
than 15 disorders have been studied with the PGRx methodology and extensive 
validation studies have been published. Patients are recruited by their physician in 
France, UK, Italy, Germany, Spain and in the US, and interviewed and/or fill a self-
questionnaire. The French PGRx ACS registry has involved 218 investigators since 
October 2013, 90% of them being cardiologists. To date, 3725 patients have been 
included. The self-reported QoL was completed at 12 months, using the EQ-5D and 
SF-12 in a sample of 619 patients who had their follow-up visit between February 
and May 2015. Results: 75% of patients were male, mean age at ACS was 67 years 
[SD= 11], and 71% had a first-lifetime ACS. 12 months after the ACS, the mean score 
of EQ-5D was 0.72 [SD= 0.24], the less favourable ratings were for pain and restriction 
in mobility, considered as “severe” in 10% and 12% of patients, respectively. Using 
the SF-12, 65% patients rated a “good” health, 80 (47%) had limited mobility, and 
70% declared some pain interfering with normal life. ConClusions: 12 months 
after ACS, patients declared a rather good QoL, despite daily limited mobility, pain 
and discomfort.
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objeCtives: Systolic heart failure (HF), is a progressive condition carrying a high 
risk of mortality, hospitalisation and having a significant detrimental impact on 
quality of life (QoL). Current therapies indicated for use in this patient population 
demonstrated beneficial effects on QoL, however the magnitude of effects remain 
debatable. This review was performed to identify QoL instruments (disease spe-
cific and generic) used in systolic heart failure, to estimate the impact of various 
pharmacological interventions. Methods: Publications resulting from Randomised 
controlled trials (RCTs) as well as post-hoc analysis of RCTs from 1996 to October 21, 
2014 were selected using pre-defined inclusion criteria. Critical appraisal of trials 
was performed using the NICE risk of bias tool. Results: A total of 37 publications 
from 33 RCTs met the inclusion criteria. The main HF-specific QoL instruments used 
were the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (8,004 patients) 
in 19 trials and the more recent Kansas City Cardiomyopathy Questionnaire (KCCQ) 
(12,101 patients) in four trials. The generic EQ-5D (VAS) was used in three trials 
whereas SF-36 was used in two trials. Four studies also reported correlations 
between end point changes in morbidity or mortality and change in QoL. Significant 
changes in QoL were found in 9 active and 5 placebo-controlled trials respectively, 
